Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prevent and cure insulin-dependent diabetes].

J F Bach1

  • 1Inserm U25, hôpital Necker, 161, rue de Sèvres, 75743 Paris, cedex 15, France. bach@necker.fr

Pathologie-Biologie
|June 5, 2003
PubMed
Summary

Immunotherapy using soluble autoantigens or anti-CD3 antibodies shows promise in slowing autoimmune diabetes progression. These treatments induce specific tolerance, proving effective in early-stage diabetic patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[T CD57+ lymphocytes in kidney transplanted patients. Phenotypic and functional study].

Presse medicale (Paris, France : 1983)·1992
Same author

[Routine application of HLA class II oligotyping. Value of automatization].

Presse medicale (Paris, France : 1983)·1992
Same author

Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome.

Transplantation·1992
Same author

Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus.

The Journal of clinical investigation·1992
Same author

A1B8DR3-associated CD8-positive T-cell expansion in HIV infection.

Lancet (London, England)·1992
Same author

[A new approach of prevention: predictive medicine].

Pathologie-biologie·1992

Area of Science:

  • Immunology
  • Endocrinology
  • Autoimmune Diseases

Background:

  • Insulin-dependent diabetes mellitus (Type 1 diabetes) is an autoimmune condition.
  • It involves the destruction of pancreatic beta cells by autoreactive T cells.
  • Current research focuses on immunotherapy to manage disease progression.

Purpose of the Study:

  • To investigate immunotherapy strategies for slowing autoimmune diabetes.
  • To evaluate the efficacy of inducing specific immune tolerance.

Main Methods:

  • Administration of soluble autoantigens.
  • Administration of monoclonal anti-CD3 antibodies.
  • Studies initially conducted in non-obese diabetic (NOD) mouse models.

Main Results:

  • Promising results observed with immunotherapy approaches.
  • Induction of specific tolerance demonstrated.
  • Efficacy shown in recently diagnosed diabetic patients.

Conclusions:

  • Immunotherapy, particularly using soluble autoantigens or anti-CD3 antibodies, is a promising approach for autoimmune diabetes.
  • These strategies can induce specific immune tolerance.
  • The findings suggest potential therapeutic applications for early-stage diabetes.

Related Experiment Videos